research Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
Cancer treatments often cause skin, nail, and hair problems.
Search
for
Sort by
Research
360-390 / 1000+ results 
research Conceptual Basis for Use of Chemotherapeutic Agents and Their Pharmacology
The conclusion is that effective cancer treatment often requires a combination of therapies, but must be carefully managed due to serious side effects and the risk of immunosuppression.
research Management of Colorectal Cancer Using Nanocarriers-based Drug Delivery for Herbal Bioactives: Current and Emerging Approaches
Nanocarriers can improve the effectiveness of herbal medicines in treating colorectal cancer.
research Copper−Doxorubicin as a Nanoparticle Cargo Retains Efficacy with Minimal Toxicity
Copper-doxorubicin nanoparticles effectively treat tumors with less toxicity.
research Selective Delivery of Tofacitinib Citrate to Hair Follicles Using Lipid-Coated Calcium Carbonate Nanocarrier Controls Chemotherapy-Induced Alopecia Areata
A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.
research VP-16-213 (etoposide): The mandrake root from Issyk-Kul
Etoposide is effective in treating several cancers, especially small cell lung cancer, with acceptable side effects.
research Etoposide sensitizes CT26 colorectal adenocarcinoma to radiation therapy in BALB/c mice
Etoposide makes radiation therapy more effective against tumors without major side effects.
research Results of Ifosfamide Combination Chemotherapy in Patients with Advanced Soft Tissue Sarcomas
Adriamycin and ifosfamide together work best for advanced soft tissue sarcomas.
research Chitosan Nanoparticles for Topical Drug Delivery in Chemotherapy-Induced Alopecia: A Comparative Study of Five Repurposed Pharmacological Agents
Phenobarbital-loaded chitosan nanoparticles are promising for preventing hair loss from chemotherapy.
research Alopecia/hair loss in all patients treated with trastuzumab and paclitaxel: myth or reality?
Most patients treated with trastuzumab and paclitaxel experience some hair loss, but it's usually not severe.
research A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients
A specific gene variant is linked to a higher risk of hair loss from chemotherapy in breast cancer patients.
research Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome
Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.
research Clinical efficacy and safety of Kanglaite injection, adjuvant cemcitabine and cisplatin chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis
Kanglaite injection with chemotherapy improves treatment and reduces side effects for advanced lung cancer.
research B/N-doped carbon nano-onions as nanocarriers for targeted breast cancer therapy
Boron/nitrogen-doped carbon nano-onions improve targeted breast cancer treatment by enhancing drug delivery and reducing side effects.
research Limited stage small cell lung cancer
Treat limited stage small cell lung cancer with chemotherapy and radiation, and consider preventive brain radiation for better survival chances.
research Eyelash Preservation During Chemotherapy and Topical Prostaglandin Therapy
A woman kept her eyelashes during chemotherapy possibly because of her glaucoma eye drops.
research UTMD Enhances Targeting of Diclofenac and Doxil® to Boost Tumor Immunotherapy
research Moderne Untersuchungsmethoden zur Evaluation von Haarausfall und Alopezie bei Frauen
Chemotherapy causes temporary hair loss in women, while Tamoxifen does not significantly affect hair, and genetics show no link between female pattern hair loss and common baldness genes.
research Understanding, recognizing, and managing toxicities of targeted anticancer therapies
Targeted anticancer therapies can cause severe side effects similar to traditional chemotherapy, but with different types.
research Cutaneous toxicities of cancer therapy
Cancer therapy can cause various skin problems, including hair loss, skin darkening, painful hand-foot syndrome, and severe skin damage.
research Design, synthesis, and biological activity of TLR7-based compounds for chemotherapy-induced alopecia
TLR7-based compounds may help manage chemotherapy-induced hair loss.
research Targeted therapy in melanoma
New treatments for advanced skin cancer are improving patient outcomes, but drug resistance and finding the right treatment combinations are still big challenges.
research 15460 Perifollicular pink halo: A potential dermoscopic marker of inflammation in central centrifugal cicatricial alopecia
Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
research The evolution of primary multimodality treatment in resectable breast cancer
Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.
research Treatment of multiple scalp basal cell carcinomas by photodynamic therapy
Photodynamic therapy was effective in treating multiple scalp basal cell carcinomas with minimal side effects and good cosmetic results.
research Topical delivery of nanoemulsions for skin cancer treatment
Nanoemulsions can effectively treat skin cancer with fewer side effects.
research Transarterial chemoembolization (TACE) combined with donafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A real-world clinical study.
The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.
research New Drugs for Leukæmia and Tumours
Some new drugs show potential for treating blood cancers but have serious side effects and need more research.
research 532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
research [Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer].
Pemetrexed with cisplatin is safer and more effective than gemcitabine with cisplatin for advanced lung cancer.